封面
市場調查報告書
商品編碼
1732822

誘導多能幹細胞生產市場-全球產業規模、佔有率、趨勢、機會和預測,按流程、產品、應用、最終用戶、地區和競爭細分,2020-2030 年

Induced Pluripotent Stem Cells Production Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Process, By Product, By Application, By End-user, By Region and Competition, 2020-2030F

出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024 年全球誘導性多能幹細胞 (iPSC) 生產市場價值為 13.5 億美元,預計到 2030 年將達到 24.5 億美元,預測期內複合年成長率為 10.44%。 iPSC 因其自我更新和分化為多種細胞類型的能力而成為再生醫學領域的變革性創新。 iPSC 是透過對皮膚或血液等成體細胞進行重新編程而獲得的,它表現出與胚胎幹細胞相似的特性,同時解決了與傳統來源相關的倫理和免疫學問題。它們的多功能性使其成為再生療法、藥物篩選和疾病建模的重要工具。隨著 iPSC 技術的進步,市場正在迅速擴張,這得益於神經病學、心臟病學和代謝紊亂領域應用的不斷成長。向個人化醫療的轉變以及使用成人衍生細胞的倫理利益進一步刺激了需求,使 iPSC 成為下一代生物醫學研究和治療開發的基石。

市場概覽
預測期 2026-2030
2024年市場規模 13.5億美元
2030年市場規模 24.5億美元
2025-2030 年複合年成長率 10.44%
成長最快的領域 藥物開發與發現
最大的市場 北美洲

關鍵市場促進因素

擴大治療應用

主要市場挑戰

生產成本

主要市場趨勢

疾病建模和藥物開發中日益成長的應用

目錄

第 1 章:產品概述

第2章:研究方法

第3章:執行摘要

第4章:顧客之聲

第5章:全球誘導性多能幹細胞生產市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 依流程(手動 iPSC 生產流程、自動化 iPSC 生產流程)
    • 按產品(儀器/設備、自動化平台、耗材及套件、服務)
    • 按應用(藥物開發和發現、再生醫學、毒理學研究、其他)
    • 按最終用戶(研究和學術機構、生物技術和製藥公司、醫院和診所)
    • 按公司分類(2024)
    • 按地區
  • 市場地圖

第6章:北美誘導性多能幹細胞生產市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 北美:國家分析
    • 美國
    • 墨西哥
    • 加拿大

第7章:歐洲誘導性多能幹細胞生產市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 歐洲:國家分析
    • 法國
    • 德國
    • 英國
    • 義大利
    • 西班牙

第8章:亞太誘導性多能幹細胞生產市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 亞太地區:國家分析
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲

第9章:南美洲誘導性多能幹細胞生產市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 南美洲:國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第10章:中東與非洲誘導性多能幹細胞生產市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • MEA:國家分析
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 11 章:市場動態

  • 驅動程式
  • 挑戰

第 12 章:市場趨勢與發展

  • 最新動態
  • 產品發布
  • 併購

第 13 章: 大環境分析

第 14 章:波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 顧客的力量
  • 替代產品的威脅

第 15 章:競爭格局

  • Lonza Group
  • Axol Biosciences Ltd.
  • Evotec SE
  • Hitachi Ltd.
  • Reprocells Inc.
  • Fate Therapeutics.
  • Thermo Fisher Scientific, Inc.
  • Merck KgaA
  • Stemcellsfactory III
  • Applied Stemcells Inc.

第 16 章:策略建議

第17章調查會社について,免責事項

簡介目錄
Product Code: 16284

The Global Induced Pluripotent Stem Cells (iPSCs) Production Market was valued at USD 1.35 billion in 2024 and is projected to reach USD 2.45 billion by 2030, growing at a CAGR of 10.44% during the forecast period. iPSCs have emerged as a transformative innovation in regenerative medicine due to their ability to self-renew and differentiate into multiple cell types. Derived by reprogramming adult cells like those from skin or blood, iPSCs exhibit properties similar to embryonic stem cells while addressing ethical and immunological concerns associated with traditional sources. Their versatility positions them as vital tools for regenerative therapies, drug screening, and disease modeling. With advancements in iPSC technology, the market is expanding rapidly, driven by growing applications across neurology, cardiology, and metabolic disorders. The shift towards personalized medicine and the ethical benefits of using adult-derived cells further bolster demand, establishing iPSCs as a cornerstone in next-generation biomedical research and therapeutic development.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 1.35 Billion
Market Size 2030USD 2.45 Billion
CAGR 2025-203010.44%
Fastest Growing SegmentDrug Development and Discovery
Largest MarketNorth America

Key Market Drivers

Expanding Therapeutic Applications

The potential of iPSCs in clinical therapy is continuously growing as they are applied to an expanding spectrum of diseases. Their ability to differentiate into various specialized cell types makes them highly promising for treating complex conditions such as Parkinson's disease, Alzheimer's, cardiovascular disorders, and diabetes. iPSCs derived from adult cells can be engineered into dopaminergic neurons, offering targeted treatment pathways and facilitating drug development for neurodegenerative conditions. Similarly, their application in cardiac regeneration is gaining traction, with researchers using iPSC-derived cardiac cells to model heart diseases and explore regenerative options post-injury. The increasing adoption of iPSCs in these therapeutic areas not only enhances treatment potential but also broadens the market for their production, as healthcare systems and patients alike seek advanced, tailored solutions.

Key Market Challenges

Cost of Production

A major limitation hindering the widespread adoption of iPSC technologies is the high cost associated with their generation and maintenance. The reprogramming of adult cells into iPSCs involves resource-intensive processes that require high-end laboratory infrastructure, advanced equipment, and skilled personnel. Furthermore, the culture media and reagents used in iPSC production are costly and must comply with strict quality standards to ensure consistency and safety. These operational expenses create significant financial barriers for both academic and commercial entities attempting to scale production for therapeutic use. Consequently, the cost of iPSC-based therapies remains high, limiting accessibility for broader patient groups and posing challenges for market scalability.

Key Market Trends

Growing Applications in Disease Modeling and Drug Development

The increasing use of iPSCs in disease modeling and pharmaceutical research is a key trend driving market growth. iPSCs can be generated from individuals with specific genetic profiles, enabling the creation of personalized disease models. These models provide valuable platforms for understanding disease mechanisms and testing drug responses in conditions such as genetic disorders, neurodegenerative diseases, and cardiovascular anomalies. Pharmaceutical companies are leveraging iPSC technology to enhance drug discovery pipelines, enabling more accurate candidate screening and reducing development timelines and costs. The rising emphasis on precision medicine further amplifies the need for iPSC-derived models, reinforcing their significance in both academic research and commercial drug development.

Key Market Players

  • Lonza Group
  • Axol Biosciences Ltd.
  • Evotec SE
  • Hitachi Ltd.
  • Reprocells Inc.
  • Fate Therapeutics.
  • Thermo Fisher Scientific, Inc.
  • Merck KgaA
  • Stemcellsfactory III
  • Applied Stemcells Inc.

Report Scope:

In this report, the Global Induced Pluripotent Stem Cells Production Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Induced Pluripotent Stem Cells Production Market, By Process:

  • Manual iPSC Production Process
  • Automated iPSC Production Process

Induced Pluripotent Stem Cells Production Market, By Product:

  • Instruments/ Devices
  • Automated Platforms
  • Consumables & Kits
  • Services

Induced Pluripotent Stem Cells Production Market, By End-user:

  • Research & Academic Institutes
  • Biotechnology & Pharmaceutical Companies
  • Hospitals & Clinics

Induced Pluripotent Stem Cells Production Market, By Application:

  • Drug Development and Discovery
  • Regenerative Medicine
  • Toxicology Studies
  • Others

Induced Pluripotent Stem Cells Production Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Induced Pluripotent Stem Cells Production Market.

Available Customizations:

Global Induced Pluripotent Stem Cells Production market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Induced Pluripotent Stem Cells Production Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Process (Manual iPSC Production Process, Automated iPSC Production Process)
    • 5.2.2. By Product (Instruments/ Devices, Automated Platforms, Consumables & Kits, Services)
    • 5.2.3. By Application (Drug Development and Discovery, Regenerative Medicine, Toxicology Studies, Others)
    • 5.2.4. By End-user (Research & Academic Institutes, Biotechnology & Pharmaceutical Companies, Hospitals & Clinics)
    • 5.2.5. By Company (2024)
    • 5.2.6. By Region
  • 5.3. Market Map

6. North America Induced Pluripotent Stem Cells Production Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Process
    • 6.2.2. By Product
    • 6.2.3. By End-user
    • 6.2.4. By Application
    • 6.2.5. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Induced Pluripotent Stem Cells Production Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Process
        • 6.3.1.2.2. By Product
        • 6.3.1.2.3. By End-user
        • 6.3.1.2.4. By Application
    • 6.3.2. Mexico Induced Pluripotent Stem Cells Production Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Process
        • 6.3.2.2.2. By Product
        • 6.3.2.2.3. By End-user
        • 6.3.2.2.4. By Application
    • 6.3.3. Canada Induced Pluripotent Stem Cells Production Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Process
        • 6.3.3.2.2. By Product
        • 6.3.3.2.3. By End-user
        • 6.3.3.2.4. By Application

7. Europe Induced Pluripotent Stem Cells Production Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Process
    • 7.2.2. By Product
    • 7.2.3. By End-user
    • 7.2.4. By Application
    • 7.2.5. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Induced Pluripotent Stem Cells Production Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Process
        • 7.3.1.2.2. By Product
        • 7.3.1.2.3. By End-user
        • 7.3.1.2.4. By Application
    • 7.3.2. Germany Induced Pluripotent Stem Cells Production Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Process
        • 7.3.2.2.2. By Product
        • 7.3.2.2.3. By End-user
        • 7.3.2.2.4. By Application
    • 7.3.3. United Kingdom Induced Pluripotent Stem Cells Production Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Process
        • 7.3.3.2.2. By Product
        • 7.3.3.2.3. By End-user
        • 7.3.3.2.4. By Application
    • 7.3.4. Italy Induced Pluripotent Stem Cells Production Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Process
        • 7.3.4.2.2. By Product
        • 7.3.4.2.3. By End-user
        • 7.3.4.2.4. By Application
    • 7.3.5. Spain Induced Pluripotent Stem Cells Production Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Process
        • 7.3.5.2.2. By Product
        • 7.3.5.2.3. By End-user
        • 7.3.5.2.4. By Application

8. Asia-Pacific Induced Pluripotent Stem Cells Production Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Process
    • 8.2.2. By Product
    • 8.2.3. By End-user
    • 8.2.4. By Application
    • 8.2.5. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Induced Pluripotent Stem Cells Production Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Process
        • 8.3.1.2.2. By Product
        • 8.3.1.2.3. By End-user
        • 8.3.1.2.4. By Application
    • 8.3.2. India Induced Pluripotent Stem Cells Production Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Process
        • 8.3.2.2.2. By Product
        • 8.3.2.2.3. By End-user
        • 8.3.2.2.4. By Application
    • 8.3.3. South Korea Induced Pluripotent Stem Cells Production Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Process
        • 8.3.3.2.2. By Product
        • 8.3.3.2.3. By End-user
        • 8.3.3.2.4. By Application
    • 8.3.4. Japan Induced Pluripotent Stem Cells Production Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Process
        • 8.3.4.2.2. By Product
        • 8.3.4.2.3. By End-user
        • 8.3.4.2.4. By Application
    • 8.3.5. Australia Induced Pluripotent Stem Cells Production Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Process
        • 8.3.5.2.2. By Product
        • 8.3.5.2.3. By End-user
        • 8.3.5.2.4. By Application

9. South America Induced Pluripotent Stem Cells Production Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Process
    • 9.2.2. By Product
    • 9.2.3. By End-user
    • 9.2.4. By Application
    • 9.2.5. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Induced Pluripotent Stem Cells Production Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Process
        • 9.3.1.2.2. By Product
        • 9.3.1.2.3. By End-user
        • 9.3.1.2.4. By Application
    • 9.3.2. Argentina Induced Pluripotent Stem Cells Production Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Process
        • 9.3.2.2.2. By Product
        • 9.3.2.2.3. By End-user
        • 9.3.2.2.4. By Application
    • 9.3.3. Colombia Induced Pluripotent Stem Cells Production Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Process
        • 9.3.3.2.2. By Product
        • 9.3.3.2.3. By End-user
        • 9.3.3.2.4. By Application

10. Middle East and Africa Induced Pluripotent Stem Cells Production Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Process
    • 10.2.2. By Product
    • 10.2.3. By End-user
    • 10.2.4. By Application
    • 10.2.5. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Induced Pluripotent Stem Cells Production Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Process
        • 10.3.1.2.2. By Product
        • 10.3.1.2.3. By End-user
        • 10.3.1.2.4. By Application
    • 10.3.2. Saudi Arabia Induced Pluripotent Stem Cells Production Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Process
        • 10.3.2.2.2. By Product
        • 10.3.2.2.3. By End-user
        • 10.3.2.2.4. By Application
    • 10.3.3. UAE Induced Pluripotent Stem Cells Production Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Process
        • 10.3.3.2.2. By Product
        • 10.3.3.2.3. By End-user
        • 10.3.3.2.4. By Application

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Product Launches
  • 12.3. Mergers & Acquisitions

13. PESTLE Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Product

15. Competitive Landscape

  • 15.1. Lonza Group
    • 15.1.1. Business Overview
    • 15.1.2. Company Snapshot
    • 15.1.3. Products & Services
    • 15.1.4. Financials (As Reported)
    • 15.1.5. Recent Developments
    • 15.1.6. Key Personnel Details
    • 15.1.7. SWOT Analysis
  • 15.2. Axol Biosciences Ltd.
  • 15.3. Evotec SE
  • 15.4. Hitachi Ltd.
  • 15.5. Reprocells Inc.
  • 15.6. Fate Therapeutics.
  • 15.7. Thermo Fisher Scientific, Inc.
  • 15.8. Merck KgaA
  • 15.9. Stemcellsfactory III
  • 15.10. Applied Stemcells Inc.

16. Strategic Recommendations

17. About Us & Disclaimer